Today: 19 July 2026
Twilio stock steadies in premarket after 5% drop as tech nerves linger
15 January 2026
1 min read

Twilio stock steadies in premarket after 5% drop as tech nerves linger

New York, Jan 15, 2026, 04:58 EST — Premarket action underway.

  • Twilio shares climbed in early premarket trading following a steep drop the day before.
  • Tech shares dipped Wednesday amid a shift toward defensive sectors, with investors digesting new developments in U.S.-China chip news.
  • Ahead of the open, traders eye major bank earnings and the latest developments in Washington-Beijing tech restrictions.

Twilio Inc’s shares climbed roughly 1.7% to $124.92 in premarket action on Thursday, rebounding after a 5.2% drop the day before that left the stock at $123.03 at Wednesday’s close.

Timing is key. Investors have been rapidly offloading pricey tech and software stocks, only to snap some back almost immediately, as earnings season expands and geopolitical news floods the tape.

Twilio’s initial rebound offers a glimpse into whether Wednesday’s selloff was driven mainly by macro factors — and if dip-buyers remain ready to jump in when the Nasdaq falters.

U.S. stocks closed down Wednesday, with the Nasdaq sliding 1% as investors shifted toward defensive sectors. Bank shares pushed lower again following a string of mixed earnings reports. “After a nice run, and so-so or mediocre earnings, you’re seeing profit-taking and consolidation,” said Michael O’Rourke, chief market strategist at JonesTrading. Reuters

Chip news added fresh jitters. Reuters reported that Chinese customs told agents this week Nvidia’s H200 AI chips can’t enter China. Domestic tech firms were warned against buying them except when absolutely necessary. “Beijing is basically stepping up its game in terms of pushing to see what bigger concessions they can get to dismantle U.S.-led tech controls,” said Reva Goujon, director at Rhodium Group. Reuters

By Thursday, the situation remained unclear. Nikkei Asia said China is drafting new purchase rules for advanced foreign AI chips — potentially signaling tighter controls instead of a total ban — though Reuters couldn’t verify the report right away.

San Francisco’s Twilio offers software tools enabling companies to integrate texts, calls, and email into their apps, alongside customer-data solutions. The stock frequently swings with shifts in risk appetite, acting almost like a pure play on growth sentiment.

Thursday’s spotlight shifts to earnings from Goldman Sachs, Morgan Stanley and BlackRock, all set to report before the opening bell, Nasdaq said. Traders will be scanning these reports for insight into dealmaking, trading volumes and broader economic signals.

Twilio shareholders are eyeing the upcoming earnings report as the next key event. MarketBeat expects the update to come on Feb. 12, but the company hasn’t officially confirmed that date.

Still, the rebound might not hold. Should tech stocks face renewed selling pressure, or if the chip dispute escalates into broader restrictions or retaliation, software shares could fall even without new company updates.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Stock Fair Value and Performance in Focus
    July 19, 2026, 3:59 PM EDT. Neurocrine Biosciences (NBIX) is viewed as near fairly valued, with shares trading at a P/E ratio of 25.7x versus a fair value estimate of 26.0x. The stock has increased 73.4% over five years and posted a 29.4% gain in the past year, though this trails some competitors. Valuation signals are mixed, with about half indicating the stock could be expensive. Investors are assessing the resilience of cash flows from current therapies alongside operational risks. Growth prospects are supported by a broad pipeline, including late-stage assets and early commercial progress, yet policy changes and concentration risks are present. The overall assessment shows a valuation that reflects tempered expectations for Neurocrine's earnings potential and profitability.
Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge
Previous Story

Kohl’s stock slides 5% as Jefferies trims target to $22, tariff ruling keeps retailers on edge

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls
Next Story

Bitcoin price nears $97,000 as ETF inflows rebound and Senate crypto bill stalls

Go toTop